ARTICLE | Company News
GSK licenses Valentis' GeneSwitch
April 12, 2001 7:00 AM UTC
GlaxoSmithKline (GSK; LSE:GSK) received a non-exclusive license to use VLTS's GeneSwitch technology, which provides control of gene expression in transgenic animals and cell cultures, in GSK's functio...